Assessing theoretical risk and benefit suggested by genetic association studies of CCR5: experience in a drug development programme for maraviroc.
Antivir Ther
; 12(2): 233-45, 2007.
Article
in En
| MEDLINE
| ID: mdl-17503665
ABSTRACT
The proliferation of published gene association studies of the CCR5delta32 mutation is of relevance to drug development of a CCR5 antagonist for HIV, in highlighting potential safety concerns. We conducted an initial review of all non-HIV gene association studies of CCR5-delta32, followed by detailed meta-analyses in the three disease areas most commonly reported. Our review indicated no consistent evidence of increased risk of susceptibility to hepatitis C virus infection or multiple sclerosis among individuals with CCR5-delta32 mutation, and suggested treatment with a CCR5 inhibitor is unlikely to have related adverse effects. There was, however, evidence to suggest rheumatoid arthritis as a potential therapeutic target for a CCR5 antagonist. Clinical evidence would be required to confirm these findings.
Search on Google
Collection:
01-internacional
Database:
MEDLINE
Main subject:
Pharmacogenetics
/
Triazoles
/
Drug Design
/
Receptors, CCR5
/
Cyclohexanes
/
HIV Fusion Inhibitors
/
CCR5 Receptor Antagonists
Type of study:
Etiology_studies
/
Prognostic_studies
/
Risk_factors_studies
/
Systematic_reviews
Limits:
Adult
/
Female
/
Humans
/
Male
Language:
En
Journal:
Antivir Ther
Journal subject:
TERAPIA POR MEDICAMENTOS
/
VIROLOGIA
Year:
2007
Document type:
Article
Affiliation country:
United kingdom